Clinical Trial: Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07890350) titled 'Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy' on Oct. 16.

Brief Summary: This is a randomized, double-blind, placebo-parallel controlled phase II study to evaluate the safety and efficacy of CM512 in patients with perennial allergic rhinitis on background therapy

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Perennial Allergic Rhinitis (PAR)

Intervention: BIOLOGICAL: CM512

Subcutaneous injection, multiple doses. Dosing every 12 weeks (Q12W) or Q24W, according to the protocol. Total treatment duration: 48 weeks.

DRUG: Placebo

Subcutaneous injection of matchi...